{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"10.9","value":"5.3"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"16.2","value":"8.3"},{"groupId":"OG002","lowerLimit":"2.8","upperLimit":"5.5","value":"3.9"},{"groupId":"OG003","lowerLimit":"4.3","upperLimit":"17.7","value":"7.1"},{"groupId":"OG004","lowerLimit":"3.1","upperLimit":"9.8","value":"5.7"},{"groupId":"OG005","lowerLimit":"7.6","upperLimit":"22.4","value":"16.2"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG006","lowerLimit":"20.2","upperLimit":"NA","value":"37.8"},{"groupId":"OG007","lowerLimit":"6.5","upperLimit":"10.3","value":"8.0"},{"groupId":"OG008","lowerLimit":"7.3","upperLimit":"18.8","value":"13.1"},{"groupId":"OG009","lowerLimit":"2.2","upperLimit":"25.2","value":"13.6"},{"groupId":"OG010","lowerLimit":"3.8","upperLimit":"15.4","value":"10.8"},{"groupId":"OG011","lowerLimit":"3.1","upperLimit":"7.7","value":"3.7"},{"groupId":"OG012","lowerLimit":"4.1","upperLimit":"10.6","value":"9.3"},{"groupId":"OG013","lowerLimit":"10.3","upperLimit":"24.4","value":"18.0"},{"groupId":"OG014","lowerLimit":"29.7","upperLimit":"65.0","value":"39.7"},{"groupId":"OG015","lowerLimit":"6.0","upperLimit":"30.1","value":"12.3"},{"groupId":"OG016","lowerLimit":"10.1","upperLimit":"31.9","value":"16.5"},{"groupId":"OG017","lowerLimit":"8.0","upperLimit":"26.6","value":"13.1"},{"groupId":"OG018","lowerLimit":"7.7","upperLimit":"18.3","value":"12.0"},{"groupId":"OG019","lowerLimit":"6.5","upperLimit":"15.3","value":"7.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"24"},{"groupId":"OG010","value":"24"},{"groupId":"OG011","value":"18"},{"groupId":"OG012","value":"23"},{"groupId":"OG013","value":"25"},{"groupId":"OG014","value":"22"},{"groupId":"OG015","value":"26"},{"groupId":"OG016","value":"27"},{"groupId":"OG017","value":"26"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"23"}],"units":"Participants"}],"description":"OS was defined as the time from the date of allocation to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the end of the trial were censored at the date of last assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with colon or rectal adenocarcinoma.","id":"OG000","title":"Cohort A1: Colon or Rectal Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with anal canal squamous cell carcinoma.","id":"OG001","title":"Cohort A2: Anal Canal Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with Pancreas Adenocarcinoma.","id":"OG002","title":"Cohort A3: Pancreas Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with esophageal squamous cell carcinoma or adenocarcinoma (including gastroesophageal (GE) junction).","id":"OG003","title":"Cohort A4: Esophageal Squamous Cell Carcinoma or Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with biliary tract adenocarcinoma (gallbladder and biliary tree, but excluding ampulla of vater cancers).","id":"OG004","title":"Cohort A5: Biliary Tract Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with carcinoid tumors.","id":"OG005","title":"Cohort A6: Carcinoid Tumors"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with neuroendocrine carcinomas (well or moderately differentiated pancreatic neuroendocrine tumor).","id":"OG006","title":"Cohort A7: Neuroendocrine Carcinomas"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ER positive HER2 negative breast cancer.","id":"OG007","title":"Cohort B1: HR Positive HER2 Negative Breast Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ovarian epithelial, fallopian tube or primary peritoneal carcinoma.","id":"OG008","title":"Cohort B2: Ovarian Epithelial, Fallopian Tube or Primary Peritoneal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with endometrial carcinoma.","id":"OG009","title":"Cohort B3: Endometrial Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with cervical squamous cell cancer.","id":"OG010","title":"Cohort B4: Cervical Squamous Cell Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with vulvar squamous cell carcinoma.","id":"OG011","title":"Cohort B5: Vulvar Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with small cell lung cancer.","id":"OG012","title":"Cohort C1: Small Cell Lung Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with mesothelioma (malignant pleural mesothelioma).","id":"OG013","title":"Cohort C2: Mesothelioma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with thyroid cancer (papillary or follicular subtype).","id":"OG014","title":"Cohort D1: Thyroid Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with salivary gland carcinoma.","id":"OG015","title":"Cohort D2: Salivary Gland Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with nasopharyngeal carcinoma.","id":"OG016","title":"Cohort D3: Nasopharyngeal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with glioblastoma multiforme.","id":"OG017","title":"Cohort E1: Glioblastoma Multiforme"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with leiomyosarcoma.","id":"OG018","title":"Cohort E2: Leiomyosarcoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with prostate adenocarcinoma.","id":"OG019","title":"Cohort E3: Prostate Adenocarcinoma"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment, had a baseline scan with measurable disease per modified RECIST 1.1 and had the intended indication. Per protocol, participants were analyzed according to disease type.","reportingStatus":"POSTED","timeFrame":"Up to approximately 86 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}